Corvus Pharmaceuticals (CRVS) Enterprise Value (2016 - 2026)

Corvus Pharmaceuticals' Enterprise Value history runs 12 years deep, the most recent figure standing at -$236.7 million for Q1 2026.

• In Q1 2026, Enterprise Value fell 4635.23% year-over-year to -$236.7 million; the TTM figure through Mar 2026 stood at -$236.7 million (down 4635.23% YoY), while the FY2025 annual figure was -$56.8 million, down 9.21% from the prior year.
• Enterprise Value for Q1 2026 stood at -$236.7 million, down from -$56.8 million in the prior quarter.
• The five-year high for Enterprise Value was -$2.9 million in Q3 2025, with the low at -$236.7 million in Q1 2026.
• The 5-year median for Enterprise Value is -$14.7 million (2025), against an average of -$31.9 million.
• The sharpest annual moves came in 2022 and 2026: Enterprise Value surged 79.26% in 2022, then sank 4635.23% in 2026.
• Corvus Pharmaceuticals' Enterprise Value stood at -$13.2 million in 2022, then advanced by 4.1% to -$12.6 million in 2023, then slumped by 311.76% to -$52.0 million in 2024, then decreased by 9.21% to -$56.8 million in 2025, then plunged by 317.12% to -$236.7 million in 2026.
• Business Quant data shows CRVS's Enterprise Value at -$236.7 million in Q1 2026, -$56.8 million in Q4 2025, and -$2.9 million in Q3 2025.